The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
Open accessAbstract
Despite the rapid and widespread integration of chimeric CD20 monoclonal antibody (mAb), rituximab, into the management of non-Hodgkin lymphoma, its efficacy remains variable and often modest when used as a single agent. To develop more potent reagents, human immunoglobulin transgenic mice were used to generate a panel of immunoglobulin G1kappa (IgG1kappa) CD20 mAbs. All reagents bound strongly to CD20(+) cells and recruited mononuclear cells for the lysis of malignant B cells. However, 2 mAbs, 2F2 and 7D8, were exceptionally active in complement-dependent cytotoxicity (CDC), being able to lyse a range of rituximab-resistant targets, such as CD20-low chronic lymphocytic leukemia (CLL), in the presence of human plasma or unfractionated blood. Further analysis showed that 2F2 and 7D8, like rituximab, redistributed CD20 into Triton X-100-insoluble regions of the plasma membrane, but that they had markedly slower off-rates. To determine whether off-rate influenced CDC, a non-complement activating F(ab')(2) antihuman kappa reagent was used. This reagent markedly slowed the off-rate of rituximab and increased its CDC activity to that of 2F2 and 7D8. Thus, with increasing evidence that mAb therapeutic activity in vivo depends on complement activation, these new CD20 reagents with their slow off-rates and increased potency in CDC hold considerable promise for improved clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CD20-targeting mAbs such as rituximab, obinutuzumab, ocaratuzumab, and ofatumumab”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Teeling et al., 2004
Experimental — accuracy not yet measuredIn the citing paper
“a variety of mAbs targeting malignant cells mediate immunostimulation upon the engagement of ADCC, ADCP, or complement-dependent cytotoxicity”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Teeling et al., 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
The kinetics of antibody binding to membrane antigens in solution and at the cell surface
Mason, D. W., & Williams, A. F. (1980) · Biochemical Journal · doi:10.1042/bj1870001 · Cited by 567
Byrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A., Park, K., Pearson, M., Waselenko, J. K., Ling, G., Grever, M. R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2153 · Cited by 508
Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Sanz, I., Rosenblatt, J., & Looney, R. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10764 · Cited by 429
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Pfeiffer, A., Böttcher, A., Orsó, E., Kapinsky, M., Nagy, P., Bodnár, A., Spreitzer, I., Liebisch, G., Drobnik, W., Gempel, K., et al. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200111)31:11<3153::aid-immu3153>3.0.co;2-0 · Cited by 401
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
Research works printed but not linked: 2
- [36]36. than recruitment of effectors. J Immunol. 1998; 161:3176-3185.
- [50]50. Schifferli JA, Steiger G, Hauptmann G, Spaeth PJ, Sjoholm AG. Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. J Clin Invest. 1985;76:2127-2133.
Cited by
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
Terwilliger, T., & Abdul-Hay, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.53 · Cited by 1,288
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Metadata
- Authors
- Teeling, J. L.
- Affiliations
- Genmab (Netherlands) (NL)
- Corresponding author
- Teeling, J. L.
- ORCID
- Teeling, J. L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-09-15
- Volume
- 104
- Issue
- 6
- Pages
- 1793-1800
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2141139539
- Cited by
- 630
- References
- 50
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 20 · 2023: 18 · 2022: 24 · 2021: 15 · 2020: 33 · 2019: 16 · 2018: 18 · 2017: 34 · 2016: 26 · 2015: 43 · 2014: 38 · 2013: 37 · 2012: 44
- FWCI
- 21.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- Tenovus
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- anti-CD20 monoclonal antibody, non-Hodgkin lymphoma, rituximab, complement-dependent cytotoxicity, chronic lymphocytic leukemia, antibody engineering, rituximab resistance
- MeSH terms
- Animals, Antibodies, Monoclonal, B-Lymphocytes, Binding Sites, Antibody, Complement System Proteins, Complement Fixation Tests, Cytotoxicity, Immunologic, Humans, Immunoglobulin G, Immunoglobulin Fab Fragments, Kinetics, Lymphoma, Non-Hodgkin, Mice, Transgenic, Leukemia, Lymphocytic, Chronic, B-Cell, Antigens, CD20, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. https://app.cochat.ai/papers/10.1182/blood-2004-01-0039
- The paper
- Teeling, J. L. (2004). Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. https://doi.org/10.1182/blood-2004-01-0039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.